PMID- 19508512
OWN - NLM
STAT- MEDLINE
DCOM- 20100810
LR  - 20181201
IS  - 1463-1318 (Electronic)
IS  - 1462-8910 (Linking)
VI  - 12
IP  - 5
DP  - 2010 May
TI  - Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic 
      colorectal cancer: a meta-analysis of seven randomized controlled trials.
PG  - 399-406
LID - 10.1111/j.1463-1318.2009.01916.x [doi]
AB  - PURPOSE: A meta-analysis was performed to assess the efficacy and safety of 
      cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic 
      colorectal cancer. METHOD: A total of 4617 patients from seven randomized 
      controlled trials were available for analysis, with 2305 patients in the 
      cetuximab group and 2312 patients in the noncetuximab group. The efficacy data 
      included progression-free survival (PFS), overall survival (OS) and overall 
      response rate (ORR). The safety data that contained overall grade 3 and 4 adverse 
      events (AEs), specific grade 3 and 4 toxicity such as acneiform rash, 
      cetuximab-related skin toxicity, diarrhoea, fatigue, neutropenia, hypertension, 
      nausea and hand-foot skin reaction are evaluated. RESULT: There was a significant 
      PFS benefit in favour of cetuximab-based therapy (HR = 0.68, 95%CI: 0.63 to 0.73) 
      and OS benefit (HR = 0.90, 95%CI: 0.81 to 1.00). The ORR was significantly higher 
      in the cetuximab-based arm (OR = 2.19, 95% CI: 1.30 to 3.68). The incidence of 
      overall grade 3-4 toxicity was significantly higher in the cetuximab arm compared 
      with the noncetuximab arm (61.2%vs 43.0%, OR = 2.32, 95%CI: 1.59-3.39). This 
      difference was mainly attributed to cetuximab-related skin toxicity (OR = 5.86, 
      95%CI: 1.38-24.88), especially acneiform rash (OR = 51.37, 95%CI: 22.75-116.02). 
      In addition, cetuximab resulted in a significant increase in grade 3 and 4 
      diarrhoea, fatigue and neutropenia, except for hypertension, nausea and hand-foot 
      skin reaction. CONCLUSION: Cetuximab-based therapy improves PFS and OS resulting 
      in better ORR vs noncetuximab therapy. Its most common and severe AE is skin 
      toxicity that should be predictable and manageable.
FAU - Liu, L
AU  - Liu L
AD  - Department of Colorectal and Anal Surgery, First Affiliated Hospital, Guangxi 
      Medical University, Nanning, Guangxi, P.R.China.
FAU - Cao, Y
AU  - Cao Y
FAU - Tan, A
AU  - Tan A
FAU - Liao, C
AU  - Liao C
FAU - Mo, Z
AU  - Mo Z
FAU - Gao, F
AU  - Gao F
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20090415
PL  - England
TA  - Colorectal Dis
JT  - Colorectal disease : the official journal of the Association of Coloproctology of 
      Great Britain and Ireland
JID - 100883611
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Acneiform Eruptions/chemically induced
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Cetuximab
MH  - Colorectal Neoplasms/*drug therapy/metabolism/mortality/pathology
MH  - *ErbB Receptors/metabolism
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Skin/drug effects
EDAT- 2009/06/11 09:00
MHDA- 2010/08/11 06:00
CRDT- 2009/06/11 09:00
PHST- 2009/06/11 09:00 [entrez]
PHST- 2009/06/11 09:00 [pubmed]
PHST- 2010/08/11 06:00 [medline]
AID - CDI1916 [pii]
AID - 10.1111/j.1463-1318.2009.01916.x [doi]
PST - ppublish
SO  - Colorectal Dis. 2010 May;12(5):399-406. doi: 10.1111/j.1463-1318.2009.01916.x. 
      Epub 2009 Apr 15.